ECCO Abstract Awards

Abstract submitters may participate in the application process for the following awards:

Best Investigator-Initiated Study (IIS) report submitted - IIS Abstract Award

The Clinical Research Committee of ECCO (ClinCom) wants to stimulate the development of high-quality Investigator-Initiated Studies (IIS) in IBD and to improve the quality of IBD clinical studies in Europe through education. In 2021, awards will be given to the 2 best congress abstracts reporting on clinical studies set up by investigators (preferably multi-centre) submitted for the ECCO Congress. Note: Studies conducted by industry will not be eligible for this award.

Responsible Committee: Clinical Research Committee of ECCO (ClinCom)
Prize: Free registration for the ECCO Congress 2022
Number of awards: 2
Who can apply: ECCO Members reporting on clinical studies set up by investigators in their abstracts. Note: ECCO Membership fee 2021 must be paid up until the abstract submission deadline.
How to apply:

In case you are not an ECCO Member yet please register for ECCO Membership 2021
Log in to the ECCO'21 Abstract submission system
At the beginning of the submission process please indicate if your abstract is qualified for the IIS Abstract Award
Please pay careful attention to the general guidelines for abstract submission
Upload your abstract for the ECCO Congress 2021
Notification of the author in the beginning of May 2021
Announcement at the ECCO'21 Congress

IIS Award 2021 Nicholas Kennedy (UK)

IIS Award 2021 Nicolas Pierre (Belgium)

Y-ECCO Abstract Award

The Young ECCO (Y-ECCO) encourages Y-ECCO Members to submit their abstract and share their research with the ECCO Community. Awards will be given to the 5 best-ranked abstracts along with a free congress registration for the following year.

Responsible Committee: Young-ECCO (Y-ECCO)
Prize: Free registration for the ECCO Congress 2022
Number of awards: 5
Who can apply: Y-ECCO Members (below 35 years of age or still in training). Note: ECCO Membership fee 2021 must be paid up until the abstract submission deadline.
How to apply:

In case you are not an ECCO Member yet please register for ECCO Membership 2021
Log in to the ECCO'21 Abstract submission system
At the beginning of the submission process please indicate if your abstract is qualified for the Y-ECCO Abstract Award
Please pay careful attention to the general guidelines for abstract submission
Upload your abstract for the ECCO Congress 2021
Notification of the author in the beginning of May 2021
Announcement at the ECCO'21 Congress

Y-ECCO Abstract Award 2021 Bobby Zhao Sheng Lo

Y-ECCO Abstract Award 2021 Bram Verstockt (Belgium)

Y-ECCO Abstract Award 2021 Craig Haifer (Australia)

Y-ECCO Abstract Award 2021 Ibrahim Al Bakir (UK)

Y-ECCO Abstract Award 2021 Mirabella Zhao (Denmark)

DOP Awards

One abstract of each digital oral presentation session has been nominated for this award by the chairs of the respective sessions.

The winners of the Top 10 DOP awards are:

DOP07: Ulcerative Colitis associated single nucleotide polymorphisms found in transcription factor binding sites effect key pathogenesis pathways and facilitate patient stratification - Dezso Modos, Ely, United Kingdom

DOP14: Ultra-high magnification endocytoscopy and molecular markers for defining endoscopic and histologic remission in Ulcerative Colitis - Marietta Iacucci, Birmingham, United Kingdom

DOP19: Urinary metabolome in newly diagnosed treatment-naïve Crohn’s Disease patients: Results from the IBDomics study - Laila Aldars-García, Madrid, Spain

DOP36: Non-invasive assessment of postoperative disease recurrence in Crohn’s Disease: A multicenter, prospective cohort study - Federica Furfaro, Rozzano, Italy

DOP41: Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study - Paulo Kotze, Curitiba, Brazil

DOP52: Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry) - Maria Chaparro, Madrid, Spain

DOP62: Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy - Neil Chanchlani, Exeter, United Kingdom

DOP64: Endoscopically injected allogeneic mesenchymal stromal cells alter the mucosal immune cell compartment in patients with ulcerative proctitis - Marieke Barnhoorn, Leiden, The Netherlands

DOP73: Antibiotic use differentially affects the risk of antidrug antibody formation during anti-TNFα therapy in Inflammatory Bowel Disease - Yuri Gorelik, Haifa, Israel

DOP87: Disease clearance as a new therapeutic target in patients with Ulcerative Colitis: A multicenter retrospective cohort study - Ferdinando D'Amico, Rozzano, Italy